Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

about

Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex.

P2860

Q35657577-C12C53C6-5AB9-4231-A200-8BEB5C7E439E

P2860

Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

Item

http://www.wikidata.org/entity/Q38020486

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

@en

type

Item

label

Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

@en

prefLabel

Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

@en

P1476

Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

@en

P2093

Bortagaray Juan

http://www.w3.org/2001/XMLSchema#string

Carol Burek

http://www.w3.org/2001/XMLSchema#string

Cristian Sager

http://www.w3.org/2001/XMLSchema#string

Juan Carlos López

http://www.w3.org/2001/XMLSchema#string

Juan Pablo Corbetta

http://www.w3.org/2001/XMLSchema#string

Santiago Weller

http://www.w3.org/2001/XMLSchema#string

Victor Durán

http://www.w3.org/2001/XMLSchema#string

P2860

Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction

Factors involved in the success of antimuscarinic treatment.

Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder.

Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins.

Adverse events after botulinum A toxin injection for neurogenic voiding disorders.

Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity.

The bladder-brain connection: putative role of corticotropin-releasing factor.

The use of botulinum neurotoxin type A (BoNTA) in urology.

Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.

Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections.

P304

763159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5402/2012/763159

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227712851

http://www.w3.org/2001/XMLSchema#string

P698

22720170

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

P932

3376763

http://www.w3.org/2001/XMLSchema#string

Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

about

P2860

P2860

Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932